<DOC>
	<DOCNO>NCT00000851</DOCNO>
	<brief_summary>To evaluate safety determine pharmacokinetic disposition stavudine ( d4T ) alone combination didanosine ( ddI ) , whether concurrent administration alters disposition either drug . To compare d4T versus d4T plus ddI respect short long term change baseline plasma HIV RNA concentration . To determine relationship , , drug exposure viral burden . In pilot study d4T ddI give eight child advance HIV 24 week , three child baseline count great 50 cells/micro liter experience 20 % increase CD4+ lymphocyte count . Based result , controlled trial regimen child less advanced HIV disease undertaken .</brief_summary>
	<brief_title>Comparison Stavudine Used Alone Combination With Didanosine HIV-Infected Children</brief_title>
	<detailed_description>In pilot study d4T ddI give eight child advance HIV 24 week , three child baseline count great 50 cells/micro liter experience 20 % increase CD4+ lymphocyte count . Based result , controlled trial regimen child less advanced HIV disease undertaken . Eligible subject receive d4T assign open manner Arm 1 , subject receive zidovudine ( AZT ) assign randomize , double blind manner Arms 2 3 . Each subject receive study drug 48 week follow : Arm 1 - d4T plus ddI , Arm 2 - d4T alone , Arm 3 - d4T plus ddI .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<criteria>Inclusion Criteria Patients must : Be onstudy , ontreatment ACTG 240 , receive AZT monotherapy prescription least 6 month immediately precede enrollment . Have laboratory evidence HIV1 infection &lt; 18 month 2 positive viral test &gt; = 18 month 2 positive viral test 2 positive test HIV antibody Have parent legal guardian willing sign consent . Prior Medication : Required : Onstudy , ontreatment ACTG 240 ( D4T AZT ) receive AZT monotherapy prescription least six month immediately precede trial . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Intractable diarrhea vomit . Current clinical laboratory Grade 3 bad toxicity . Concurrent Medication : Excluded : Concurrent use antiretroviral agent provide study , immunomodulators ( IVIG corticosteroid ) , investigational drug except ACTG 254 ACTG 219 . Chemotherapy active malignancy . Patients follow prior condition exclude : Reached ACTG 240 define endpoint , permanently ACTG 240 study treatment . Prescription AZT recipient may receive &gt; 6 week d4T ddI previously . Subjects chemotherapy active malignancy . Prior Medication : Excluded : Prescription AZT recipient may receive &gt; 6 week d4T ddI previously .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Stavudine</keyword>
</DOC>